vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and National Bank Holdings Corp (NBHC). Click either name above to swap in a different company.

National Bank Holdings Corp is the larger business by last-quarter revenue ($126.8M vs $85.1M, roughly 1.5× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 16.4%, a 6.4% gap on every dollar of revenue. Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 14.0%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

Old National Bank is an American regional bank with nearly 200 retail branches operated by Old National Bancorp and based in Chicago and Evansville, Indiana. With assets at $48.5 billion and 250 banking centers, Old National Bancorp is the largest financial services bank holding company headquartered in Indiana and one of the top 30 banking companies in the U.S. Old National Bank has locations in Illinois, Indiana, Iowa, Kentucky, Michigan, Minnesota, Tennessee, and Wisconsin.

FDMT vs NBHC — Head-to-Head

Bigger by revenue
NBHC
NBHC
1.5× larger
NBHC
$126.8M
$85.1M
FDMT
Higher net margin
FDMT
FDMT
6.4% more per $
FDMT
22.8%
16.4%
NBHC
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
14.0%
NBHC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FDMT
FDMT
NBHC
NBHC
Revenue
$85.1M
$126.8M
Net Profit
$19.4M
$20.8M
Gross Margin
Operating Margin
17.3%
Net Margin
22.8%
16.4%
Revenue YoY
8508900.0%
Net Profit YoY
139.1%
-14.2%
EPS (diluted)
$0.43
$0.46

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
NBHC
NBHC
Q1 26
$126.8M
Q4 25
$85.1M
$100.6M
Q3 25
$90.0K
$108.9M
Q2 25
$15.0K
$104.5M
Q1 25
$14.0K
$102.1M
Q4 24
$1.0K
$101.3M
Q3 24
$3.0K
$106.0M
Q2 24
$5.0K
$97.6M
Net Profit
FDMT
FDMT
NBHC
NBHC
Q1 26
$20.8M
Q4 25
$19.4M
$16.0M
Q3 25
$-56.9M
$35.3M
Q2 25
$-54.7M
$34.0M
Q1 25
$-48.0M
$24.2M
Q4 24
$28.2M
Q3 24
$-43.8M
$33.1M
Q2 24
$-35.0M
$26.1M
Operating Margin
FDMT
FDMT
NBHC
NBHC
Q1 26
Q4 25
17.3%
19.0%
Q3 25
-67983.3%
39.6%
Q2 25
-396373.3%
39.8%
Q1 25
-383007.1%
29.2%
Q4 24
34.3%
Q3 24
-1704400.0%
37.6%
Q2 24
-849120.0%
32.5%
Net Margin
FDMT
FDMT
NBHC
NBHC
Q1 26
16.4%
Q4 25
22.8%
15.9%
Q3 25
-63195.6%
32.4%
Q2 25
-364386.7%
32.6%
Q1 25
-342657.1%
23.7%
Q4 24
27.8%
Q3 24
-1461433.3%
31.2%
Q2 24
-699060.0%
26.8%
EPS (diluted)
FDMT
FDMT
NBHC
NBHC
Q1 26
$0.46
Q4 25
$0.43
$0.42
Q3 25
$-1.01
$0.92
Q2 25
$-0.98
$0.88
Q1 25
$-0.86
$0.63
Q4 24
$0.72
Q3 24
$-0.79
$0.86
Q2 24
$-0.63
$0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
NBHC
NBHC
Cash + ST InvestmentsLiquidity on hand
$402.7M
$472.8M
Total DebtLower is stronger
$202.1M
Stockholders' EquityBook value
$505.7M
$1.7B
Total Assets
$566.7M
$12.6B
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
NBHC
NBHC
Q1 26
$472.8M
Q4 25
$402.7M
$417.1M
Q3 25
$305.1M
$555.6M
Q2 25
$293.2M
$296.5M
Q1 25
$321.4M
$246.3M
Q4 24
$424.9M
$127.8M
Q3 24
$501.9M
$180.8M
Q2 24
$541.9M
$145.0M
Total Debt
FDMT
FDMT
NBHC
NBHC
Q1 26
$202.1M
Q4 25
$54.5M
Q3 25
$54.7M
Q2 25
$54.4M
Q1 25
$54.6M
Q4 24
$54.5M
Q3 24
$54.4M
Q2 24
$54.4M
Stockholders' Equity
FDMT
FDMT
NBHC
NBHC
Q1 26
$1.7B
Q4 25
$505.7M
$1.4B
Q3 25
$369.0M
$1.4B
Q2 25
$420.9M
$1.4B
Q1 25
$469.7M
$1.3B
Q4 24
$510.6M
$1.3B
Q3 24
$552.9M
$1.3B
Q2 24
$588.3M
$1.2B
Total Assets
FDMT
FDMT
NBHC
NBHC
Q1 26
$12.6B
Q4 25
$566.7M
$9.9B
Q3 25
$424.0M
$10.2B
Q2 25
$473.6M
$10.0B
Q1 25
$515.7M
$10.1B
Q4 24
$560.4M
$9.8B
Q3 24
$604.0M
$10.0B
Q2 24
$620.1M
$10.0B
Debt / Equity
FDMT
FDMT
NBHC
NBHC
Q1 26
0.12×
Q4 25
0.04×
Q3 25
0.04×
Q2 25
0.04×
Q1 25
0.04×
Q4 24
0.04×
Q3 24
0.04×
Q2 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
NBHC
NBHC
Operating Cash FlowLast quarter
$28.6M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
33.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
NBHC
NBHC
Q1 26
Q4 25
$28.6M
$162.4M
Q3 25
$-46.5M
$52.4M
Q2 25
$-43.4M
$32.3M
Q1 25
$-47.8M
$39.6M
Q4 24
$-134.6M
$155.3M
Q3 24
$-29.4M
$47.0M
Q2 24
$-30.2M
$31.9M
Free Cash Flow
FDMT
FDMT
NBHC
NBHC
Q1 26
Q4 25
$28.5M
Q3 25
$-46.6M
Q2 25
$-43.4M
Q1 25
$-48.4M
Q4 24
$-138.4M
Q3 24
$-31.2M
Q2 24
$-30.6M
FCF Margin
FDMT
FDMT
NBHC
NBHC
Q1 26
Q4 25
33.5%
Q3 25
-51765.6%
Q2 25
-289620.0%
Q1 25
-345635.7%
Q4 24
-13837100.0%
Q3 24
-1038966.7%
Q2 24
-611840.0%
Capex Intensity
FDMT
FDMT
NBHC
NBHC
Q1 26
Q4 25
0.1%
Q3 25
101.1%
Q2 25
440.0%
Q1 25
4507.1%
Q4 24
378600.0%
Q3 24
59266.7%
Q2 24
6980.0%
Cash Conversion
FDMT
FDMT
NBHC
NBHC
Q1 26
Q4 25
1.47×
10.13×
Q3 25
1.48×
Q2 25
0.95×
Q1 25
1.64×
Q4 24
5.51×
Q3 24
1.42×
Q2 24
1.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FDMT
FDMT

Segment breakdown not available.

NBHC
NBHC

Net Interest Income$108.8M86%
Noninterest Income$18.0M14%

Related Comparisons